Who is sponsoring NCT03846076?

NCT03846076 is sponsored by Volen Ivanov.

What drugs are being tested in NCT03846076?

Interventions in NCT03846076: Cognitive behavioral therapy.

What condition does NCT03846076 study?

NCT03846076 studies Olfactory Reference Syndrome.

Is NCT03846076 still recruiting?

NCT03846076 is currently completed. Last updated 2 November 2021.

Last reviewed 2021-11-02 · How we verify

NCT03846076

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Internet Delivered CBT for Olfactory Reference Syndrome

Completed NA Last updated 2 November 2021

What this trial tests

NA trial testing Cognitive behavioral therapy in Olfactory Reference Syndrome in 15 participants. Completed in 12 April 2021.

Timeline

4 March 2019

Primary endpoint
12 April 2021

12 April 2021

Quick facts

Lead sponsor	Volen Ivanov
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	4 March 2019
Primary completion	12 April 2021
Estimated completion	12 April 2021
Sites	1 location across Sweden

Drugs / interventions tested

Cognitive behavioral therapy

Conditions studied

Olfactory Reference Syndrome — all drugs for Olfactory Reference Syndrome →

Sponsor

Volen Ivanov

Who can join

18 and older, any sex, with Olfactory Reference Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of the study is to test the feasibility and efficacy of, a manual based, Internet-delivered, cognitive behaviour therapy (CBT) for patients with Olfactory Reference Syndrome (ORS) who live in Sweden. The secondary aim is to investigate smell sensitivity and body odor in these ORS-patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cognitive behavioral therapy

Trials testing the same drug.

NCT06956417 — REhabilitation of MEMory Symptoms After BRain Concussion · NA · recruiting
NCT06866639 — Cognitive Behavioural Therapy/Metacognitive Therapy for Low Self Esteem · NA · not yet recruiting
NCT06511518 — Cognitive Behavioral Therapy for Cancer-related Fatigue in Patients With Cancer Receiving Palliative Systemic Treatment · NA · recruiting
NCT06189534 — Cognitive Behavior Therapy for Social Media Addiction, Insomnia, and Family Relationship Among Individuals With Social M · NA · unknown
NCT06174350 — Evaluation of the Effect of Cognitive Behavioral Therapy in Individuals Exposed to Earthquakes · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03846076 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Volen Ivanov
Last refreshed: 2 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03846076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing